Clinical Trial Update: A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of Apremilast (CC-10004) for moderate to severe plaque psoriasis of the scalp; study completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-04